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ABSTRACT 
More than 40% of new chemicals developed in the pharmaceutical industry have poor 
solubility in aqueous solutions. Active Pharmaceutical ingredients (API) cannot reach 
their molecular targets in the body if the drug remains undissolved in the gastrointestinal 
system. One way to approach this problem is by using solubilizing agents. One such 
agent is a thermo-responsive, tri-block co-polymer which is marketed as “Soluplus®” 
(SP) by BASF Corporation. A part of this project is to thoroughly characterize various 
phase properties of SP such as cloud points and gel points temperatures. In current 
application, SP was incorporated into the creams formulations as an emulsifier to 
determine the effects on API solubility. The analysis included centrifugations and UV-
Vis studies to determine the concentrations of the API in the cream’s phases. The results 
of the cloud and the gel points of SP curves matched the curves from polymers 
containing the individual building blocks of SP. The results of the current application 
showed that the presence of SP in acid and salt Ibuprofen increased the partitioning of 
API into the water phase. 
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1 INTRODUCTION 
 
1.1 The Solubility Issues of Active Pharmaceutical Ingredients (API’s) 
More than 40% of new chemicals developed in the pharmaceutical industry have 
poor solubility in aqueous solutions.
1,2
 Solubility is the tendency of any chemical in any 
physical form to dissolve in a solid, liquid, or gaseous solvent to form a homogeneous 
solution, which can be dependent on the nature of the solvent, temperature, and pressure. 
The International Union of Pure and Applied Chemistry (IUPAC) defines solubility as a 
proportion of specific solute in a specific solvent for saturated solution.
3
 Equilibrium 
occurs when dissolution and phase joining have the same rate.
1
 Dynamic equilibrium is 
the cause of solubility resulting from simultaneous and opposite processes of dissolution 
and phase joining.  
Solubility plays a major role in the pharmaceutical industry. The Biopharmaceutic 
Classification System (BCS) is a scheme developed to classify each drug based on drug 
solubility and gastrointestinal permeability. Solubility and permeability were chosen 
because they control the rate and extent of drug absorption. The solubility of the drug 
determines the highest-dose strength of an immediate release product.
1,4
 For a drug to be 
considered to have a very high dose strength, it should be soluble in 250 ml or less in 
aqueous solution within the range of 1-7.5 pH scale.
5
 Each drug is classified into four 
fundamental classes based on their solubility and cell permeability (Table 1, Figure 1). 
 
  
2 
 
 
 
 
 
 
 
 
 
Low solubility will require a dose escalation until the drug concentration in the 
blood is within the therapeutic drug concentration range. In oral applications, high doses 
can cause toxicity in the gastrointestinal system, and eventually lead to reduction in 
patient compliance. In addition, developing a high dose drug is challenging due to 
difficulty of formulating powders and tablets.
2
 Around 50-60% of the drugs are classified 
as Class II drugs – low solubility and high permeability.6  In some cases, even small 
increases in the solubility can improve the bioavailability of the drug. 
 
Class Solubility Permeability 
I High High 
II Low High 
III High Low 
IV Low Low 
†
See Ref. 4. 
Table 1. The Biopharmaceutic Classification System† 
Figure 1. The BCS is illustrated in terms of volume of aqueous that needed to dissolve 
anticipated dose for solubility, and cell permeability.
17
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Researchers in the pharmaceutical industry are focusing on ways to overcome the 
solubility issues. Methods to improve solubility include:  
 Addition of polar functional groups: placing a polar functional group in the structure 
of a molecule that is not soluble in aqueous solution in order to improve the solubility 
of the drug.
 
Example: sulindac is an inactive drug, but after reduction it becomes 
active as sulindac sulfide.
7
 
 
 Polymeric micelles: cores/shells structures formed by amphiphilic block copolymers. 
These polymeric micelles can entrap hydrophobic drugs and be used for intravenous 
delivery.
8
 Example: diblock polymer polylactic acid – polyethylene glycol (PLA-
PEG) and triblock polymer PLA-PEG-PLA are been used to help increase drug 
delivery.
9
 
 
 pH modification and salt forms: in this approch, the drug undergoes pH modification 
in order to be more soluble, or it generates a salt. Currently this is the most common 
approach because 70% of drugs are ionizable and slightly basic.
9
 Examples: 
Telmisartan is an insoluble drug at pH of 3-9. However, the current formulation 
includes sodium hydroxide, which increase the pH.
10
 Atazenavir is insoluble in water 
as a free base. The salt form improves significantly the bioavailability of the drug.
9,11
  
 
 Solid state modification: amorphous forms: this approach includes a change of the 
solid state to make the drug more soluble. Drugs with a stable crystal form have 
higher lattice energy and are much less soluble than disordered amorphous forms.
 9
  
 
 Co-solvency and surfactant solubilization: conjugation of a solvent with a surfactant, 
and in some cases with pH modification, to increases solubility in water.
9
 Examples: 
ethanol is 80% of Tacrolimus formulation; glycerin is 32.5% of Epinephirine 
formulation etc.  
 
1.2 Usage of Polymeric Micelles to Increase Drug Solubility 
A solubilizing agent that was studied in my project is Soluplus®, which forms 
polymeric micelles to help solubilize drugs. Polymeric micelles are formed from the self-
assembly of amphiphilic block copolymers, which contain a combination of hydrophilic 
and hydrophobic segments in an aqueous environment.
12
 The self-assembly of 
amphiphilic block copolymers in water is based on non-polar and hydrophobic 
interactions between the lipophilic core-forming polymer chains, leading to better 
4 
 
aqueous solubility.
13
 The ability to form a core-shell structure is entropically favored, and 
occurs above their critical micelle concentration (CMC).
12
 The hydrophobic moieties are 
separated from the outside aqueous surrounding, and thus form an inner core where the 
hydrophilic moieties form a shell or corona (Figure 2).
12,14
  
This unique behavior attracted the interests of pharmaceutical’s development 
researchers for solubilization of poorly soluble drugs.
14
 Polymeric micelles have high 
drug-loading capacities in their hydrophobic inner core,
14
 and they can solubilize poorly 
water-soluble drugs by incorporating them in this core. The micelles can deliver the drug 
to target sites when the concentration exceeds the intrinsic solubility of the drug – which 
makes them more available in the body.
15
 Moreover, they have a slow rate of dissociation 
that enabling retention of loaded drugs for longer periods of time, increasing the 
accumulation of a drug at the target site.
14 
In addition, a drug inside the core is protected 
from any contact with the gastrointestinal tract, which can lead to degradation and 
metabolism.  
 
 
 
Figure 2. The formation of a drug-loaded polymeric micelle in aqueous media 
occurs through self-assembly of amphiphilic copolymers, resulting in a 
hydrophobic core and hydrophilic corona.
12
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Two types or more of monomeric units, in our case three, which differ in their 
solubility, are the building blocks of copolymers. They are organized into a polymeric 
chain as random, block, and graft (the focus of my project) copolymers (Figure 3). My 
project focuses on graft copolymer Di-block (A-B) and tri-block (A-B-A)-copolymers 
which can be prepared from the same hydrophilic and hydrophobic monomeric units.
16
 
The most abundant and efficient hydrophilic block for both di- and tri-block copolymers 
is poly (ethylene oxide), which is more commonly referred to as - poly(ethylene glycol) 
(PEG).
12
 
PEG’s high solubility in water and hydration makes it the most popular 
hydrophilic block polymer.
 
Tri block copolymers that contain PEG and hydrophobic 
propylene oxide units are used the most as tri-block pharmaceutical polymers.
16
  
 
  
 
Figure 3. Copolymer structures. The structural type of 
copolymers: random, block, and graft.
16 
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1.3 Soluplus® 
Soluplus® (SP) is a novel amphiphilic polyvinyl caprolactam (PVLC)-polyvinyl 
acetate (PVAc)-polyethylene glycol (PEG 6000) tri-block graft copolymer made by the 
BASF cooperation. The hydrophilic PEG block segments are the backbone while the 
lipophilic monomers PVLC and PVAc are the side chains.  The structure is shown in 
Figure 4. The molecular weight of SP is 118,000g/mol with a PVCL-PVAc-PEG mass 
ratio of 57:30:13, respectively. It is a free flowing white to slightly yellowish granule.
17
  
SP was mainly design for the preparation of solid solutions. Studies showed that it 
is soluble in organic solvents such as acetone, ethanol, DMF, and methanol. Moreover, 
SP is ideal for hot melt extrusion with excellent extrudability and easy processing 
because its glass transition temperature is fairly low. This low temperature helps APIs 
with high or low melting points to be extruded easily without degradation.
17
 Also, SP is 
thermally stable and can withstand the temperatures as high as 220°C without 
degradation.
18
   
   
 
Figure 4. SP structure. The three different block 
polymers shown are PVCL, PVAc, and PEG 
with ratio of 57:30:13.
17 
PEG: 13 
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Due to its amphiphilic structure, SP forms polymeric micelles along with the 
APIs, and can increase the solubility of insoluble drugs in aqueous solution.
18,19
  Figure 5 
shows an illustration of the mechanism of the interaction between SP and an API.  
The stability of polymers with API’s is dependent on their length and their 
molecular weight. Polymers with higher molecular weight, such as SP can have greater 
entanglement with drug molecules. Moreover, since it has multiple binding sites in the 
lipophilic residues, it has even better entanglement compared to polymers that lack those 
sites. Thus, SP is allowing the drug to maintain in the solution for longer time. SP also 
showed stronger intermolecular interactions with the API, creating better stabilization 
and prevention of crystallization, and hence, the drug release is slower.  
 
 
   
Solubility of various oral drugs in water was shown to increase after the addition 
of SP.
17
 Because of this, SP also is believed to have potential to increase solubility of 
Figure 5. Interaction between SP and an 
API.
19 
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drugs in topical creams. Thus, my thesis aims to determine the magnitude of solubility 
change after the addition of SP to ibuprofen in topical creams.  
 
1.4 Physical Properties  
Physical properties such as molecular weight, boiling point, melting point, color 
and density are basic properties that important to know especially for a new chemical 
developed in the market. Other properties such as cloud point and gel point, are important 
physical characterizations of polymers that should be known.   
In general, cloud point is the initial temperature where the solution gets cloudy.
20
 
By definition it is the temperature where phase separation starts. The appearance of 
cloudiness is due to the formation of polymer-rich emulsion droplets, and the 
concentration of the polymer affects the cloud points. The lower critical solution 
temperature (LCST) is the lowest temperature where the solution gets cloudy.
21
  
Gel points is the temperature where the gel appears for the first time.
22
 IUPAC 
defines gel point as the "point of incipient network formation in a process forming a 
chemical or physical polymer network, where the gel point is expressed as an extent of 
chemical reaction."
23
  
Beside the importance of knowing the physical properties for safety reasons, 
cloud points and gel points are valuable properties in terms of solubility and sensory 
evaluations. The solubility of API with SP is based of formation of the self-assembly and 
creation of micelles, while the cloudiness is inversely since it is a phase separation. 
Moreover, clear gel that gets cloudy after rubbing it on the skin, could lead to bad sensory 
evaluation and penitent compliance.  
9 
 
1.5 Transdermal Drug Delivery System 
Transdermal drug delivery systems deliver therapeutically appropriate amounts of 
a drug to the body across the skin.
24
 and are designed to reach systemic blood levels.
25
 
They provide alternatives to oral, intravascular, subcutaneous, and transmucosal routes.
26
 
The human skin contains two distinct layers: the stratified avascular cellular epidermis, 
and an underlying dermis of connective tissue (Figure 6).
25
 With regards to drug 
penetration, the outer layer, stratum corneum (SC), is the barrier that provides the rate 
limiting step.
24,25
  The stratum corneum is an approximately 30-microons thick structure 
and renews itself at the same time it acts as a barrier and protects against environmental 
toxins. 
 
 
  
 
The major penetration route of drugs across the SC is through the intercellular 
region, which is a space that contains lipids and glycoproteins.
24
 The permeation of a 
Figure 6. Schematic representation of skin structure.
27
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drug through the skin depends on the drug’s physiochemical properties, such as: 
molecular weight (less than 500Da), pKa of the drug, stability of the formulation, binding 
affinity, its lipid solubility  and high lipophilicity. Also, the permeation depends on low 
therapeutic dose, integrity and thickness of the SC, and skin hydration.
25,26
    
Transdermal systems have been an important drug delivery technology for the 
past 30 years.
24,25,26
  This technology, in which the drug penetrates the skin and gets into 
the systemic circulation, has several advantages over oral delivery applications:
24,25
  
 Avoids chemically hostile gastrointestinal (GI) environment and doesn’t have GI 
physiologic contraindications of oral route. 
 
 Avoids the first-pass inactivation by the liver when the drug is absorbed and irritate 
the GI mucosa.  
 
 Increases patient compliance.  
 
 Offers an alternative to patients who are having trouble swallowing tablets/capsules 
and overcoming it by crushing the tablets. This can destroy any controlled release 
characteristics of the tablets.  
 
 Allows administration of drugs with narrow therapeutic window and effective use of 
drugs with short biological half-lives. 
 
 Offers better flexibility of dosage since it can be easily terminated by removal of the 
transdermal drug.  
 
1.6 Ibuprofen (Ibp) for Use in Topical Formulations 
An inflammatory response is activated by the human body when there is tissue 
damage. Increasing vascular permeability, local damaged tissues and dilation of local 
blood vessels are parts of the inflammatory reaction that occurs. The inflammatory cells 
release arachidonic acid metabolites, such as cyclooxygenase (COX) enzyme, in order to 
heal the damaged tissues.
28  
Nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce  
prostaglandin synthesis by COX inhibition at the site of pain and inflammation.
29
 The 
11 
 
first type of NSAIDs were oral salicylate compounds that were extracted from willow 
bark.
28,29
 Today, NSAID drugs, which are the number one prescribed drug in the world, 
have more than 25 different oral applications, but only a few topical formulations that are 
commercially available.
28,29
 
However, oral NSAIDs have some critical adverse effects such as increased risk 
of bleeding, kidney dysfunction, and GI irritation and ulceration.
28
 Topical formulations 
are a way to overcome the adverse effects of oral NSAID. They are applied locally, 
around the affected area, and can provide effective concentration at the target tissues 
without producing the systemic levels.
29
  
Ibuprofen (Ibp, named from (RS)-2[4- isobutylphenyl] propanoic acid), an 
NSAID drug that BASF Corp. is marketing, is designed to help with reducing pain, fever, 
and inflammation. The free acid structure is not soluble in water but is soluble in organic 
solvents. Ibp has a phenyl moiety (Figure 7) that absorbs light at 272nm, by measuring in 
a UV range, allowing research data on the drug to be easily investigated. 
 
 
12 
 
 
 
Advil Gel, Nurofen Gel, and Ibuactive are examples of different types of topical 
pain relievers that include Ibp. Currently, Ibp is present in many places in the world as a 
topical cream, however are not available in the United States, and they are in the process 
of being filed for approach. Thus, Ibp would make a good candidate for my study.  
  
Figure 7. The structure of free-acid Ibp (top) and dodium salt Ibp (bottom).
30 
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2 MATERIAL AND METHODS 
 
2.1 Source of All Chemicals 
A cream is classified as an emulsion, which is by definition a colloidal dispersion 
comprising two immiscible liquids, usually water and oil. The oil phase is dispersed as 
droplets in the aqueous phase. Cream requires an oil and water phase, as well as an 
emulsifier to stabilize the dispersion.
31
 An emulsifier is an amphiphilic molecule that has 
a hydrophilic part and lipophilic part, and when added to an oil in water mixture, situates 
at the interface. This arrangement anchors the hydrophilic part in water and the lipophilic 
part into oil.
32   
SP is an amphiphilic polymer and therefore could act as an emulsifier. 
Thus, SP was incorporated into the cream formulations as a co-emulsifier. 
In these cream recipes, water and glycerol, the humectant which keeps the 
solution moist, are the primary components of the water phase. The cetyl alcohol and 
cocoyl caprylocaprate are the oil phase. Cetyl alcohol imparts the desired consistency and 
helps to enhance the stability and viscosity of the cream. SP, CS20, and PS60 serve as the 
emulsifiers.  All chemicals were provided by BASF Corporation and are listed in Table 2 
as the components of the cream formulations, along with the percentage of each. For the 
Ibp solubility studies the 95% ethanol was used its name was UltraPure 190 Proof Ethyl 
Alcohol (1/4 micron filtration), and it came from Fisher Scientific. 
 
2.2 Instrument Descriptions 
  UV/Vis Absorption:  Perkin-Elmer Lambda 650 UV-Vis Spectrometer and 
Agilent Technologies Cary 60 UV-Vis Spectrometer were used in lower critical solution 
temperature, and in determining concentrations of Ibp. 
14 
 
Table 2.  Cream recipes for Base Cream #1 and Base Cream #2 
Name of 
Compound 
Compendial Name 
Broad 
Classification 
% 
Base Cream #1 
DI water water Solvent  71 
Kollisolv G99 glycerol  humectant  5 
Kolliwax CA cetyl alcohol  consistency 
factor  
10 
Kollicream 3C cocoyl caprylocaprate emollient  10 
Kollihor CS 
20  
macrogol cetostearyl ether 20  emulsifier  1/4
†
 
Soluplus®  PVCL-PVAc-PEG emulsifier 3/0
†
 
Base Cream #2 
DI water water Solvent  71 
Kollisolv G99 glycerol  humectant  5 
Kolliwax CA cetyl alcohol  consistency 
factor  
10 
Kollicream 3C cocoyl  caprylocaprate emollient  10 
Kolliphor 
PS60  
polysorbate 60  emulsifier  1/4
†
 
Soluplus®  PVCL-PVAc-PEG emulsifier 3/0
†
 
†
Total percentage of emulsifier is 4%, rather it is just of one emulsifier or 1% 
with 3% SP. 
 
Lambda 650 has a temperature control application that can heat or cool the sample. 
However, it doesn’t measure the actual temperature in the sample itself. This application 
was used in the cloud points study. In addition, a small stir bar was placed inside the 
sample cuvette while the absorbance was collected during the cloud points study. 
Experimental parameters: the wavelength for the cloud points study was 500nm which is 
a wavelength at which nothing in the solution absorbs. The path length was 1 cm, the data 
interval was 1nm, and the scan speed was 266.75nm/min. each measurement took 
15 
 
between 15-20 minutes. For Ibp studies the path length was 1 mm and the range of 
wavelength was between 310-250nm. Most of the measurements in the Ibp studies were 
measured using Cary 60 UV-Visible spectrometer. The scan parameters in this 
instruments were wavelength range between 310-250nm, path length of 1mm, and 0.5nm 
for data interval and scan rate of 300nm/min.   The method remained the same throughout 
all the experiments. The Lambda 650 UV-Vis did not have baseline correction setup, 
hence, it was done manually. The Cary 60 has a base line correction, and it was used with 
majority of the samples analysis.   
Formulation station:  this included a programed hot plate, IKA® Eurostar power 
control visc 4 blade mixer, and all the ingredients from Table 2.  
Centrifuge: Sorvall RC-5B Refrigerated Superspeed Centrifuged by Du-Pont 
Instrument, was the centrifuge that was used in determination of Ibp study. The speed 
was 18,000 rpm and the temperature could not drop below 25°C and could not be higher 
than 35°C.  
2.3 Procedure 
Determination of Cloud Points. Cloud points were measured by using optical 
transmission of UV-Vis as a function of temperature in different concentrations of SP in 
aqueous solution. Different sample compositions, ranging from 0.5-40% SP in aqueous 
solution, were made and stored in the cooling room.  The measurements of the 
absorbance readings included setting up the instrument as illustrated in Figure 8.  A 
temperature probe was placed inside the solution using a ring stand with a three finger 
clamp in a way that it did not interfere the beam of the instrument. The probe was 
connected to a Vernier Labquest controller that measured the temperature every 30 
16 
 
seconds. The temperature probe was used to ensure the temperature reading corresponded 
to sample itself, since the temperature controller was capable of monitoring only the 
temperature of the sample block as a whole.  In order to prevent interference from room 
light, the instrument’s sample chamber was covered with black cloth. 
 
  
 
 
In the next step, the solution temperature was set higher than the cloud point 
(around 45°C), and once it reached the temperature, the cooling/heating turned off. After 
turning off the heat, the absorbance readings were measured every 3-5 seconds. At high 
temperatures the sample was very opaque, resulting a high absorbance reading that 
corresponding to the scattering of the light that doesn’t go through the sample. As the 
temperature decreased the solution became less opaque, thus decreasing the apparent 
absorbance readings.  
The absorbance readings and temperature data were collected until the solution 
was cooled to a temperature below the cloud point – around 20°C. Each concentration 
was analyzed at least 3 times and then a plot of absorbance readings versus temperature 
Figure 8. UV-Vis setup for cloud points 
17 
 
for each composition was plotted.  At high temperature, the absorbance reading is high, 
but when the sample is cooled down, the absorbance reading decreased. Once the 
solution becomes “clear” (SP is not typically clear even at low temperatures) the curve 
levels off. The cloud point was defined as the point on the absorbance reading vs. 
temperature plot where the absorbance began to rise abruptly – i.e., the inflection point. 
This point was determined by taking the best fit line for the most linear regions before 
and after the absorbance greatly increased (see Figure 9).  
 
 
 
Determination of Gel Points. Aqueous solvent samples were prepared with SP 
concentrations from 5% to 30% at 2.5% increments. To measure the gel point for a given 
concentration, a 400mL beaker filled with water was placed on a hot plate with a ring 
y = 0.0164x - 0.0757 
R² = 0.9763 
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R² = 0.9842 
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Figure 9. Absorbance vs temperature for determination of cloud point. The red and green 
points were used to determine the best fit lines for defining the inflection point (CP). 
CP 
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holder. A lab stand was set up with two clamps, where the lower clamp was used to hold 
the test tube of SP solution being tested and the higher clamp was used to hold a 
temperature probe. The test tube was submerged in the water bath so that the entirety of 
SP solution was under water, but so that the opening at the top was above the water level 
(Figure 10). The temperature probe was connected to a digital thermometer used for 
reading the temperature of the SP solution. Reading the temperature from the actual SP 
solution, and not from the water bath, is vital to ensure accurate readings. Also, the 
temperature probe was held so that its tip was in the middle of the SP solution, and not 
touching the glass of the test tube. This allowed the reported temperature to correspond to 
the actual sample solution. This also allowed for stirring the bath to provide a uniform 
temperature throughout.  
 
 
 
Each solution was heated and checked multiple times before the gel point was 
recorded. To determine a gel point the test tube was turned by 90° at a given temperature 
Figure 10. Gel point set up 
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for 5 seconds. If the solution did not exhibit any motion once it turned, the gel point was 
recorded. If the solution moved, then it was returned to the water bath. (Fig.11). Each 
sample was checked 3 times, and the average temperature was calculated and reported.   
 
 
 
Sample Formulation/Preparation. The cream formulations followed the recipes in 
Table 2.The formulation procedures followed approximately those given in the original 
recipes where SP was added as an emulsifier and substituted part of the original 
emulsifier.  All ingredients (Table 2) were added to a large beaker typically 4500 mL 
(Figure 12A). The mixture was heated to approximately 60°C on a programmable hot 
plate (Figure 12B). Once the target temperature was reached, the solution was mixed for 
2 minutes using a mixer equipped with a flat 4-blade impellor at a high mixing rate 
Figure 11. Determination of a gel 
point. The solution was turned 90 
degrees, and once it did not exhibit 
any movement the gel points was 
called. 
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(approx. 400 rpm; Figure 12C). The hot plate was then replaced with a non-heated plate 
and the solution was mixed for an additional 15-20 minutes at a low mixing rate (approx. 
200rpm). Once the cream formed, it was transferred to a storage jar (Figure 12D). The 
stored creams were allowed to sit undisturbed at room temperature (~22°C) and under 
ambient lighting for at least 24 hours before analysis.  
 
    
 
Figure 12. Images of the cream formulation process: (A) all the ingredients are added 
together to a 400ml beaker. (B) the ingredients are heated up to 60°C (C) once temp was 
reached, the ingredients are mixed at high speed for two minutes, then at lower rate for 
another 15-20 minutes, resulting (D) the cream was transferred to a storage jar.   
B 
A 
C 
D 
21 
 
Determining concentrations of Ibp. For the solubility studies, different creams 
were formulated in order to determine how the presence of SP affects the distribution of 
Ibp (or its sodium salt form) between the phases of typical creams (water, oil, and solid).  
Descriptions of the sample variations are given in Table 3.  
* Only modifications to the standard formulations are given.  All other ingredients are 
incorporated as described in the original formulations (Table 2). 
 
After the creams were left undisturbed at room temperature (~22°C) and under 
ambient lighting for at least 24 hours, each cream was divided into four (4) centrifuge 
tubes with approximately 15g of sample placed in each tube (Figure 13).  
The tubes were centrifuged for 90 minutes at 18,000 rpm. After centrifuging the 
tubes, 3 phases were observed: oil which was on top, solid (cream) in the middle and 
water was observed in the bottom (Figure 14). Each of the liquid phases were extracted at 
this point using digital pipettes. The oil phase was easy to the collect because it was on 
top. However, the water phase was a bit more challenging because the solid phase 
“blocked” it. To collect the phase, part of the solid phase was moved aside using a 
spatula.  The mass of each sample extraction was measures, and by density and final 
Table 3. Experimental formulations based on BASF Base Creams 1 and 2* 
Base Cream 2 Base Cream 1 
Sample 
# 
g H-
Ibp 
g  
Na-
Ibp 
g 
SP 
g  
PS60 
Sample 
# 
g H-
Ibp 
g 
Na-
Ibp 
g 
SP 
g  
CS20 
203 1     4 103 1     4 
204 1   3 1 104 1   3 1 
205   1   4 105   1   4 
206   1 3 1 106   1 3 1 
207 5     4 107 5     4 
208 5   3 1 108 5   3 1 
209  5  4 -     
210  5 3 1 - 
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mass the volume was calculated. The mass was measured, and using the density the 
volume was found (Figure 15). 
Then two samples in a range of 0.2-1ml from each liquid phase were diluted with 
95% ethanol and were analyzed by UV-Vis spectroscopy.  In the end 16 samples (8 each 
from the oil and water phases) of each jar of cream were analyzed (Figure 16). Table 4 
gives the sample numbers, as well as the calculations to find the concentrations of the 
Ibp. 
 
  
 
.   
Figure 13. Dividing the cream into four centrifuged tubes 
Sample 
207 
4 centrifuged 
tubes, each with 
15g of Sample 
207-1 207-3 207-2 207-4 
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Figure 15. Each liquid phase was extracted into small beakers 
Figure 14. Three phases for a cream: oil on top, solid in the middle and 
water on the bottom. 
Oil Phase  
Water Phase  
Solid 
Phase  
207-1 207-3 207-2 207-4 
207-1 
OP 
207-2 
OP 
207-3 
OP 
207-4 
OP 
Extracted 
oil phase  
207-1 
WP 
207-2 
WP 
207-3 
WP 
207-4 
WP 
Extracted 
water phase  
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Some spectra were collected without automatic baseline correction. For these 
samples the baseline correction was done manually as illustrated in Figure 17A.  A linear 
baseline was determined from the recorded spectrum in the 285-305-nm range and was 
subsequently subtracted from the original spectrum.  Some spectra were collected with 
the automatic baseline turned on, so no manual process was needed (see Fig. 17B for a 
representative spectrum). 
Figure 16. Two samples from each liquid phase were diluted 
with 95% ethanol for evaluation by UV-Vis spectroscopy. OP 
is the oil phase and the WP is the water phase. Cuvette 1 OP A 
is one of the two samples that contains oil phase from 
centrifuge 1.  
207-1 OP 207-2 OP 207-3 OP 207-4 OP 207-1 WP 207-2 WP 207-3 WP 207-4 WP 
OP 1 OP 4 OP 3 OP 2 WP 1 WP 2 WP 3 WP 4 
A B A B A B A B A B A B A B A B
B 
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Figure 17.UV-Vis spectra of Ibp solutions (A) is a spectrum from Lambda 650 
UV-Vis, which doesn’t have a base line correction, and the correction was made 
manually. (B) is a spectrum from the Cary 60 which has baseline correction.  
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The absorbance of each sample was determined at the peak maximum that was 
found around 272nm for H-Ibp and at 273nm for Na-Ibp, and used to determine a 
concentration from the calibration curves shown in Fig. 18. 
 
 
 
From these equations [H-Ibp] = A/19.9095 and [Na-Ibp] = A/29.441 the 
concentrations of diluted samples were calculated.   
The following calculations proceed in order to find the average concentration 
(g/ml) in each centrifuged tube: first the calculated molarity of original sample was found 
by: 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 ∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
= 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑚𝑜𝑙𝑎𝑟𝑖𝑡𝑦 𝑜𝑓 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒  
Then to find the number of moles: 
y = 19.9095x 
R² = 0.9912 
0
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Figure 18. Calibration curves for determination of molarity of 
Ibp in the phases. The absorbance for H-Ibp was collected at 
272nm, and the absorbance for Na-Ibp was collected at 
273nm. The solvent that was used is 95% ethanol. 
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𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 𝑜𝑓 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 ∗ 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑚𝑙)
1000
= #𝑚𝑜𝑙𝑒𝑠 
To find the concentration in g/ml in each phase, the numbers of moles were 
converted to grams (MW=206.29g/mol for H-Ibp and 228.29 for NaIbp), and the result 
was divided by the volume of total sample. Figure 19 shows a representative example of 
the calculations that were done for Cream 207 in order to find the average concentration 
of Ibp in each phase of the cream.  
 
 
 
Statistical Analysis for the Results. The first statistical test that was performed on 
the data was the Q-test in order to disregard values that were statistically out of range. 
The results of the comparisons – SP present or absent, the type of the emulsifier, and the 
type of the Ibp should be checked for statistical differences. To determine the statistical 
Sample 
207
volume 
of total 
sample 
(ml)
volume 
of 
sample 
exracted 
(ml)
Dilution 
factor in 
alcohol
Abs at 
peak
Concentra
tion of 
diluted 
sample 
(M)
Calculated 
Molarity of 
original 
sample(M) 
moles of 
Ibp
grams 
of Ibp g/ml 
Indiv 
Samples
overall Std Dev.
1 OP A 1.23 0.0619 0.619 0.000587 0.121 0.128
1 OP B 1.24 0.0621 0.621 0.000589 0.122 0.128
2 OP A 1.28 0.0643 0.643 0.000646 0.133 0.133
2 OP B 1.31 0.0656 0.656 0.000659 0.136 0.135
3 OP A 1.14 0.0575 0.575 0.000552 0.114 0.119
3 OP B 1.21 0.0609 0.609 0.000585 0.121 0.126
4 OP A 1.13 0.0565 0.565 0.000542 0.112 0.117
4 OP B 1.20 0.0602 0.602 0.000577 0.119 0.124
1 WP A 0.127 0.00638 0.0638 0.000457 0.0942 0.0132
1 WP B 0.150 0.00753 0.0753 0.000539 0.111 0.0155
2 WP A 0.126 0.00632 0.0632 0.000465 0.0959 0.0130
2 WP B 0.129 0.00648 0.0648 0.000477 0.0984 0.0134
3 WP A 0.119 0.00599 0.0599 0.000425 0.0876 0.0124
3 WP B 0.126 0.00634 0.0634 0.000450 0.0928 0.0131
4 WP A 0.108 0.00543 0.0543 0.000395 0.0815 0.0112
4 WP B 0.118 0.00591 0.0591 0.000430 0.0887 0.0122
10.0
10.0
Averages (g/mL)
0.006350.200
1.00
0.126
Calculations 
0.0130 0.00125
7.153
7.359
7.094
7.276
0.120
0.0144
0.0132
0.949 0.128
0.0127
0.0117
1.005
0.9610
0.9584
0.134
0.122
Figure 19. A screen shot of a representative spreadsheet for determining [H-Ibp] in 
creams (Cream 207 shown). 
28 
 
differences the one-way analysis of variance (ANOVA) was used. ANOVA tests between 
the means of three or more checks to see if there are any significant differences between 
the means of three or more independent or unrelated groups.
33
 The Levene’s test was 
used to check if the samples have variances that are equal across groups or samples. The 
data failed the test since we have different variances.
34
 Welch and Brown-Forsythe tests 
were used to confirm significance due to unequal variance as determined by a Levene’s 
test. Pairwise comparisons were determined by the Games-Howell post-hoc test that 
checks if the groups are significantly different when the group has unequal size and or 
unequal variances. Changes were considered to achieve significance when p < 0.05, 
which corresponds to a confidence interval of 95% or better. All statistical analyses were 
conducted using SPSS statistical software (IBM, Armonk, NY, USA, release 21). 
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3 RESULTS 
 
3.1 Phase behavior of SP 
Determination of Cloud Points. Each sample of SP with various concentrations, in 
a range between 0.5-40%, were analyzed three times as describe in Section 2.3. The 
average temperature and the standard deviation are presented in Table 4 and plotted in 
Figure 20. 
  
 
 
 
Cloud Points for SP 
% Wt T (°C) SD (°C) % Wt T (°C) SD (°C) 
0.5 29.9 0.519 16 28.2 0.0586 
1 30.9 0.315 17 27.7 0.268 
2 30.4 0.21 18 28.4 0.397 
2.5 30.8 0.485 19 28.6 0.264 
3 30.6 0.794 20 28 0.183 
4 29.5 0.159 21 28.6 0.158 
5 29.4 0.027 22 28.4 0.732 
6 28.7 0.137 23 29.3 0.351 
7 28.4 0.0586 24 28.8 0.329 
8 27.6 0.371 25 28.6 0.267 
9 27 0.275 26 29 0.0417 
10 26.7 0.361 27 29.2 0.0347 
11 27 0.148 28 30.2 0.114 
12 27.2 0.227 29 30.7 0.241 
13 28.2 0.306 30 28.8 0.0289 
14 28.3 0.469 35 29.4 0.433 
15 27.6 0.155 40 30.9 0.24 
Table 4. Cloud points results: the average temperature and standard deviation for 
each SP concentration 
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The results show that overall, the cloud points decreases between 1-10% SP 
concentration range and then increases with increasing SP concentration. This behavior 
of SP resembles the behavior of PVCL, one of SP’s polymer blocks (Figure 20).35 
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Figure 20. The average cloud point temperatures for each SP concentration 
presented in Temp vs. SP Concentration graph. The error bars corresponds to the 
+/- standard deviation. 
31 
 
 
 
Determination of Gel Points. Each SP concentration was analyzed three times as 
described in Section 2.3.2. The range of the concentrations was between 5-30%. The 
upper sol-gel transition temperature, USGT (the temperature at which the gel becomes 
liquid again) was analyzed between concentrations of 12.5-17%, and the results of the 
study are presented in Table 5. 
 
 
Figure 21. Cloud Points of PVCL in aqueous solution. The shape of the SP curve is 
similar to the to the PVCL one. The ω2 represents the partial weight fractions of 
water and PVCL.
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Table 5. Gel points results: the Avg temperature and Standard deviation for each SP 
concentration. Concentration below 10% never gelled. 
Gel Points for SP   
Concentration 
%wt 
5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 
Avg Temp °C N/A N/A 53.7 45.7 42.9 40.1 39.6 38.3 33.5 32.9 30.5 
StDev N/A N/A 1.15 2.29 1.44 1.22 1.15 0.38 0.12 0.06 1.4 
Avg USGT °C    60.3 63.8 68.5      
StDev    1.5 1.0 0.5      
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The plot of sol-gel transition temperature versus the composition of SP is shown 
in Figure 22. The gel points for a different tri-block polymer contains two PEG blocks – 
PEG-PLGA-PEG – were studied and the results showed similar behavior as it was 
observed with SP (see Figure 23).
36
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Figure 23. Gel Points of tri block copolymer that contains two PEG units in aqueous 
solution. The shape of the SP curve is similar to the PEG copolymer.
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Figure 22. The Average gel point for each SP concentration presented in 
Temp vs. SP Concentration graph. The concentrations below 10% never 
gelled. 
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3.2 Ibp Solubility Studies 
Each Base Cream #2 (BC2) was analyzed 3 times as describe in section 2.3. Each 
Base Cream #1 (BC1) was analyzed twice.  All the average concentrations of Ibp from 
centrifuge tubes were calculated and tabulated. Overall, there were approximately 12 
repetitive measurements of Ibp concentrations in BC2 and 8 for BC1 creams. Table 4 
shows a representative set of calculations that were performed to determine the 
concentration of Ibp in each centrifuge tube, and then for each cream. Then the average 
concentrations of all the three runs were calculated along with the corresponding standard 
deviations (see Table 6 and 7 for BC #1, and Table 8 and 9 for BC #2). The concentration 
of Ibp was calculated in g/mL, however the final average concentrations are given in 
mg/mL. The total average of Ibp concentrations in the creams were plotted as graphs.  
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Cream 
Code 
Batch #1 Batch #2 Average StDev 
mg/ml mg/ml mg/ml mg/ml 
103 
59.3 56.0 
56.6 2.3 
59.4 55.5 
58.5 54.4 
56.7 53.0 
104 
52.4 46.4 
49.5 5.1 
59.0 44.9 
49.6 45.6 
53.3 44.4 
105 
3.08 4.71 
3.4 0.84 
2.27 4.17 
2.35 3.43 
3.33 3.70 
106 
n/a 6.35 
7.3 1.0 
n/a 8.63 
n/a 7.58 
n/a 6.63 
107 
173 182 
179 6.3 
175 180 
169 184 
 
187 
108 
153 173 
160 6.2 
155 160 
159 160 
156 164 
 
 
 
 
 
 
 
 
Table 6 Individual and Averaged Concentrations of Ibp in the oil phase for BC1 Batches 
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Table 7. Individual and Averaged Concentrations of Ibp in the water phase for BC1 
Batches 
Cream 
Code  
Batch #1   Batch #2 Average  StDev 
mg/ml mg/ml mg/ml mg/ml 
103 
1.98 1.47 
1.77 0.29 
2.14 1.64 
2.09 1.50 
1.93 1.44 
104 
3.06 1.28 
2.3 1.1 
3.89 1.00 
3.21 1.07 
3.06 1.66 
105 
12.7 12.4 
12.6 0.24 
12.9 12.4 
12.5 12.4 
13.0 12.6 
106 
13.6 13.4 
13.5 0.21 
13.6 13.3 
13.8 13.2 
13.5 13.2 
107 
10.3 10.3 
12.4 2.1 
12.1 11.6 
15.5 12.1 
 
14.9 
108 
17.0 14.5 
15.4 1.5 
17.8 13.3 
14.8 13.9 
16.0 15.4 
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Table 8.Individual and Averaged Concentrations of Ibp in the oil phase for BC2 Batches 
 
  
Cream Code 
Batch #1 Batch #2 Batch #3 Average StDev 
mg/ml mg/ml mg/ml mg/ml mg/ml 
203 
57.4 59.0 63.2 
59.9 3.9 
56.2 60.1 62.5 
56.2 56.4 66.0 
57.7 56.7 67.5 
204 
32.4 44.0 44.2 
41.6 2.4 
30.9 47.6 48.8 
31.0 46.5 49.4 
31.4 46.7 46.8 
205 
4.45 2.66 5.21 
4.01 0.74 
3.92 3.08 4.41 
4.11 3.86 4.89 
3.73 3.76 3.81 
206 
n/a n/a n/a 
n/a n/a 
n/a n/a n/a 
n/a n/a n/a 
n/a n/a n/a 
207 
128 171 184 
166 33.3 
134 178 191 
122 181 197 
120 n/a 214 
208 
139 150 158 
152 11.2 
140 158 160 
145 153 159 
135 166 171 
209 
1.69 6.03 3.89 
4.4 2.1 
1.66 5.98 4.38 
1.78 5.22 4.38 
n/a 8.62 4.34 
210 n/a 
4.20 6.12 
5.7 1.4 
3.93 5.62 
4.24 7.86 
5.74 7.95 
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Table 9. Individual and Averaged Concentrations of Ibp in the water phase for BC2 
Batches 
Cream 
Code 
Batch #1 Batch #2 Batch #3 Average StDev 
 mg/ml mg/ml mg/ml mg/ml mg/ml 
203 
0.294 4.38 0.138 
0.62 0.44 
0.540 3.61 0.172 
0.600 8.23 1.29 
0.729 3.83 1.21 
204 
1.55 2.466 2.43 
2.13 0.44 
1.52 2.37 2.59 
1.57 2.646 2.43 
1.62 2.186 2.14 
205 
12.13 11.27 12.6 
12.1 0.69 
12.77 11.32 11.8 
12.67 11.27 13.1 
12.56 11.15 12.5 
206 
12.14 13.3 14.05 
13.4 0.70 
12.76 13.5 14.1 
12.67 13.7 14.37 
12.57 13.5 13.89 
207 
14.4 9.54 8.84 
10.8 1.9 
13.2 9.50 9.44 
12.7 9.68 10.23 
11.7 n/a 9.61 
208 
5.78 7.85 6.21 
6.4 1.1 
5.65 7.54 5.67 
5.23 7.58 5.64 
5.28 8.16 5.78 
209 
51.4 60.3 57.1 
57.1 4.8 
51.3 61.7 58.6 
51.2 62.6 58.5 
50.5 63.3 59.0 
210 
58.6 59.8 60.4 
59.6 0.57 
58.8 59.8 59.5 
59.1 59.9 60.5 
59.8 60.0 59.4 
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Effect of SP on Ibp Solubilities in BC2 formulations. In Table 2 in Section 2.3 
there is a full description of the sampling codes. In Figure 24 the average concentrations 
are presented as columns and the standard deviation represented by the error bars.  
Figure 24A and 24B show that free acid Ibp (H-Ibp) is partitioning significantly 
more into the oil phase compared to salt Ibp (Na-Ibp), seen in both 1% Ibp creams 
(Creams 203, 204) and 5% Ibp creams (Cream 207, 208). The concentrations of H-Ibp 
was higher in 5% creams, however, it did not increase by 5-fold as it was expected – 
~60mg/ml in Cream 203 and ~165mg/ml in Cream 207.  As shown in Figure 24A, Cream 
006 exhibit no oil phase. Another observation from the Figure 24A and 24B, is that 1% 
H-Ibp cream without SP (203) had higher concentration of H-Ibp in the oil phase 
compare to the creams with SP (204). For the 5% Cream type, the results were not 
significantly different to 95% level of confidence and suggest that SP does not have a 
large effect on the solubility of H-Ibp in the oil phase.  
As expected, since Na-Ibp is soluble in water, the results in Figures 25A and 25B 
show that Na-Ibp is partitioning significantly more in the water phase compared to H-Ibp. 
These observations are true for both 1% Ibp and 5% Ibp creams. Creams with 5% Na-Ibp 
(Creams 209&210) had around 5-fold increasing from 1% Na-Ibp (Creams 205&206). 
For H-Ibp, Cream 207 had more than 5-fold increasing with regards to Cream 203. 
Cream 208 had around 3-fold increasing with regards to Cream 204. Creams that contain 
SP tend to have higher concentrations of H-Ibp in the water phase compare to creams 
without SP. These results are true for all creams except Cream 208 (5% H-Ibp, 3g SP), 
which had less Ibp concentration in the water phase compared to cream 207 (H-Ibp, no 
SP). This result is unexpected, as SP as an emulsifier and as a solubilizing agent should 
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helped H- and Na-Ibp become more soluble in the water phase, compared to the PS60 
emulsifier alone. Creams with Na-Ibp had around the same concentrations in the water 
phase in creams with SP and without. All the results are statistically different to 95% 
confidence. 
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Figure 24. Average concentrations of ibuprofen in the oil phases in BC2 formulations 
containing (A) 1% H-Ibp in 203&204, 1% Na-Ibp in 205&206 (B) 5% H-Ibp in 
207&208, 5% Na-Ibp in 209&210. Error bars represented the standard deviation. 
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Effect of SP on Ibp Solubilities in BC1 formulations. Similar to what happened in 
BC2, H-Ibp in BC1 partitioned mostly into the oil phase, while Na-Ibp partitioned mostly 
into the water phase. Unlike Cream 206, which did not produce an oil phase, Cream 106 
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Figure 25. Average concentrations of ibuprofen in the water phases in BC2 
formulations containing (A) 1% H-Ibp in 203&204, 1% Na-Ibp in 205&206 (B) 5% 
H-Ibp in 207&208, 5% Na-Ibp in 209&210. Error bars represented the standard 
deviation. 
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produced a significant amount of oil phase. Moreover, as it seen in Figure 26A, the 
concentration of Na-Ibp was higher compared to 105 (the same formulation but without 
SP; see Table 3). This implies that SP helped to partition more Na-Ibp into the oil phase 
of this cream formulation.  Creams that contained SP and 1% Na-Ibp had higher 
concentrations in the oil phase compared to creams that did not contain SP. The 5% H-
Ibp formulations showed more partitioning into the oil phase of Cream 107 (no SP) 
compared to Cream 108 (SP). These results were different to 95% confidence interval.  
Figure 26B shows that creams with SP had higher concentrations of both types of 
Ibp in the water phase. However, only in creams with Na-Ibp and SP the results were 
different to 95% confidence interval. There were no significant differences to within a 
95% confidence interval between creams that had SP and cream that did not for both 1% 
and 5% H-Ibp cream types in the water phase.  
Comparison Between the Emulsifiers PS60 and CS20. When comparing the oil 
phase of BC1 and BC2, H-Ibp partitioned slightly more into the oil phase of Cream 203, 
compared to 103. Cream 104 had higher concentration of H-Ibp in the oil phase 
compared to Cream 204 (Figure 27A). Both Cream 107 and Cream 108 had slightly 
higher concentrations of H-Ibp in the oil phase compared to Cream 207 and Cream 208 
respectively (Figure 27B). 
Cream 205 had slightly higher concentration of Na-Ibp compared to Cream 105. 
Cream 206 did not exhibit any oil phase, whereas Cream 106 did (Figure 27C).  
The comparison between 103 and 203 and 106 and 206 are significant different to 
95% confidence interval, however the rest of the results are not. Overall, it seems that 
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CS20 together with SP as emulsifiers effect the solubility of that H- and Na-Ibp in the oil 
phase. PS60 tends to have better solubility of H- and Na-Ibp in the oil phase without SP.  
For the water phase, all BC1 creams had higher concentrations of H- and Na-Ibp 
compared to the BC2 creams (see Figures 27A-C). Though, only the significant 
difference to within a 95% confidence interval was between the emulsifier in Cream 108 
and 208.  
The results in Figures 28 show that creams with SP and CS20 as emulsifiers had 
higher concentrations of H- and Na-Ibp in final forms. This suggests that the combination 
of both emulsifiers helps to partition the H- and Na-Ibp into the water phase much more 
compared to one emulsifier or PS60 with SP.  
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4 DISCUSSION  
 
 The physical properties of each new product on the market should be studied and 
evaluated for future use. Hence, the physical properties of SP, a new potential product, 
were studied in my research. The cloud point curve of SP shown in Figure 20 is similar to 
that of PVCL in Figure 21. The gel point curve of SP (Figure 22) also is similar to the 
curve of a different triblock copolymer that contains PEG (Figure 23). From these results, 
it likely that PVCL may be responsible for the cloud point behavior of SP.  PEG is 
probably not the part responsible for the sol-gel behavior of SP, but these speculations 
will require future investigations. This topic will be discussed further in the Future Work 
section.  
SP was designed to be used as a solubilizing agent in oral drugs and specifically 
for hot melt extrusion processing. Another potential application is the use of SP as a 
solubilizing agent in topical creams and gels. My research evaluated the partitioning of 
the APIs (H- and Na-Ibp) in skin cream formulations, where SP was incorporated into the 
cream formulations as a co-emulsifier. H-Ibp is insoluble in aqueous solution and soluble 
in organic solvents, while Na-Ibp is soluble in aqueous phases and rather insoluble in oil 
phases. Thus, the unaided partitioning of H-Ibp primarily into the oil phase and Na-Ibp 
primarily into the water phase was expected and observed. Another observation from this 
study was the higher concentrations of H- and Na-Ibp in the water phase in creams that 
contained SP compared to creams without it. However, the higher concentration of H-Ibp 
in the water phase in Cream 207 (no SP) compared to Cream 208 (w/ SP) was 
unexpected.  
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SP, PS60 and CS20 are the emulsifiers that were used in the creams formulations 
(see Section 2.3). By definition, they are amphiphilic polymers (PS60 and CS20 are fairly 
small compared to SP) that can potentially form polymeric micelles and entrap the drug 
in their core. The formation of the polymeric micelle occurs only when the concentration 
of the emulsifier exceeds the critical micelle concentrations (CMC),
37
 The concentration 
above which micelles form. The CMC values are influenced by the molecular weight of 
the polymer and the hydrophobicity of the core forming block copolumers.
38  
Hence, it 
was expected that SP’s CMC was smaller compared to PS60 (7.6 mg/L,17 and 18.9 
mg/L,
39 
respectively).
 
These values are suggesting that SP formed more polymeric 
micelles with the H- and Na-Ibp entrapped inside the core and eventually causing it to 
dissolve better in the aqueous environment. Since SP is soluble in water, the drug should 
exhibit a higher concentration in the water phase compared to the drug without SP. In 
addition, the volume of the water phase was larger and some of the oil phase was slightly 
smaller in creams that contained SP compared to creams that did not. A possible 
explanation could be the formation of SP micelles around oil droplets in addition to the 
SP micelles around H- and Na-Ibp through a similar mechanism.  
Drug loading capacity, the maximum amount of drug contained within the 
polymer, could be another aspect that suggests the differences in the water phase between 
creams that contained SP and creams without it. The compatibility of the drug and a 
polymer used for encapsulation, as well as the chemistry of the hydrophilic core of the 
polymer, can suggest how efficient the drug loading capacity is. Similar structure and 
polarity between the drug and polymer can lead to a better compatibility. Also, good 
compatibility between the drug and polymer core can help with drug entrapment and 
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micelle stability. Modification and derivatization, such as adding a longer hydrophobic 
block, were shown to help the drug loading and the micelle stability.
38,40 
 The drug 
loading capacity also increases with increasing concentration of the drug – the higher the 
concentration, the bigger the micelles that are formed, leading to a higher drug loading 
capacity. When increasing the concentration of the polymer, the drug loading increased 
until a plateau is reached and the micelle is fully saturated.
40
  
A possible explanation of why the concentration of H-Ibp in Cream 208 (5% H-
Ibp, 3g SP) was determined to be lower when compared to Cream 207 (5% H-Ibp, 0g SP) 
could be that the hydrophilic portion of the PS60 (the ethoxylated sorbitan) is interacting 
with the SP, rendering less available from both SP and PS60 to dissolve the drug. Also, it 
could be that SP is entrapping PS60 into the core, and leading to less PS60 to dissolve the 
drug.  
 
In my study, the numbers of moles of H- and Na-Ibp that might be inside one mole of SP 
core were estimated using simple calculations. The calculations included finding the 
molarity of H- and Na-Ibp in the water phase of the creams with and without SP, along 
with the molarity of SP. To do that, the average concentration of the H- and Na-Ibp in the 
water phase converted to molarity using the following equation: 
𝑎𝑣𝑔
𝑔
𝑚𝑙
∗
1𝑚𝑜𝑙
206.29𝑔
∗
1000𝑚𝐿
1𝐿
=
𝑚𝑜𝑙
𝐿
 
The molarity of H- and Na-Ibp in creams without SP was subtracted from the 
molarity of H- and Na-Ibp in cream with SP. The results of the subtraction were divided 
by the molarity of SP in the cream. Throughout all the study, the concentration of SP in 
the cream formulation was consisted as 3g/100mL, and the molarity (based on a molar 
mass of 118,000 g/mol; Section 1.3) was found to be 0.000254mol/L for all the 
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calculations. The final results gave us the "excess" number of moles of H- and Na-Ibp 
that were made soluble by the presence of SP core. Tables 10 and 11 give the molarities 
and the number of moles of Ibp per 1 mole of SP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results from Tables 10 and 11 show that the number of mole of H- and Na-
Ibp per one mole of SP increases with increasing the percentage of the drug inside the 
cream (Cream 107/108 compared to 103/104). This is consistent with data found in the 
literature – higher concentrations of drugs lead to a larger drug loading capacity.40 
Table 10. Calculation series and number of mole of Ibp per one mole of SP in 
BC1 
Cream 
Code 
M Ibp 
w/o SP 
M Ibp 
w/ SP 
Difference M of SP 
1 mol Ibp 
/ 1 mol SP 
103 0.0086 
 0.0026 
0.00025 
10 
104 
 
0.011 
105 0.055 
 0.0037 14 
106 
 
0.059 
107 0.060 
 0.014 56 
108 
 
0.074 
Table 11. Calculation serious and number of mole of Ibp per one mole of SP in BC2 
Cream 
Code 
M Ibp 
w/o SP 
M Ibp 
w/ SP 
Difference M of SP 
1 mol Ibp 
/ 1 mol SP 
203 0.0030 
 0.0073 
0.00025 
29 
204 
 
0.010 
205 0.053 
 0.0056 22 
206 
 
0.059 
207 0.052 
 -0.022 -85 
208 
 
0.031 
209 0.25 
 0.011 43 
210 
 
0.26 
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Polysorbate 60 (PS60), macrogol cetostearyl ether 20 (CS 20) and SP were the 
emulsifiers in this study. PS60 contains a C18 group as the hydrophobic tail, and an 
ethoxylated sorbitan as the hydrophilic head (Figure 29).  
 
 
 
 
 
Macrogol cetostearyl ether 20 (CS20) is a polyethoxylated (PEG 20 chain) 
esterified to a range of C16s and C18s. Overall, the structures of the two emulsifiers are 
fairly similar, especially when comparing the hydrophobic chains. Moreover, in half of 
the cases, the CS20 is going to also have a C18 saturated lipid chain. This will anchor the 
inside of the oil droplet in both emulsifiers, leaving the ethoxylated portions exposed to 
the water. Another comparison between the PS60 and CS20 is the hydrophilic-lipophilic 
balance (HBL) values, which are 14.9 and 15 respectively. These values suggest that 
functionally the two emulsifiers have roughly the same balance of hydrophobic to 
hydrophilic character and will function similarly. 
Figure 29. Polysorbate 60 structure. Contains C18 as the hydrophobic tail, and an 
ethoxylated sorbitan as the hydrophilic head.
41 
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 There were slightly higher concentrations of 1% and 5% H-Ibp in creams that 
contain CS20 compared to creams that contained PS60. A possible explanation for this 
result is that when SP was absent, Ibp was dissolve slightly more into the CS20 
polymeric micelles in the water phase, particularly with 1% H-Ibp concentrations. With 
higher API concentrations, this effect is essentially washed out. Since Na-Ibp is already 
an order of magnitude more soluble, the effect is minimal. The presence of SP assist in 
the solubilization of mainly H-Ibp and has an additive effect to the CS20 solubilization. 
Also, the amount of H-Ibp observed decreased in the oil phase in creams with SP as was 
expected. This is because there is more SP in the aqueous phase, and SP solubilizes more 
Ibuprofen when taken from the oil phase.  
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5 CONCLUSION & FUTURE WORK 
  
5.1 Conclusions  
Since SP has shown to help the solubility of API in oral application, the long term 
goal of this project is to show that SP can also increase the solubility of API in topical 
creams and gels. Another goal of this project is to characterize the physical properties of 
SP, due to SP being a new product on the market.  
My thesis is pioneer work that was done on physical properties of SP and the 
current topical applications. The cloud and the gel points of SP were found using UV-Vis 
and hot water bath with digital thermometer, respectively. The results of the curves 
matched the curves from polymers containing the individual building blocks of SP.  
For the current application, it was found that the presence of SP in H-Ibp and Na-
Ibp increased the partitioning of API into the water phase due to a significantly increased 
solubilzation capacity; this would result in improved API concentration in contact with 
the skin for oil in water emulsion.  
 
5.2 Future work  
The studies describes in my thesis could be followed by future investigation in a 
number of possible directions.  
 
Physical Properties. The gel points were found in a standard method, but can be 
performed more accurate. A better, more scientific way to measure the gel points is to 
measure the viscosity of SP in different concentration in aqueous solutions. To do that, a 
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rheometer instrument and viscosity studies will be needed. This is currently another 
branch of this project.  
My thesis focused on the cloud and gel points of SP as a whole. But, to evaluate 
which part of the copolymer is responsible for the cloudiness and the gelation of SP, each 
of the building blocks will have to evaluate separately. The cloud points method in 
section 2.3.1 is an accurate method and should be used in the future. For the gel points, 
the viscosity of SP and each of its building block should be evaluated using rheometery.  
 
Current Applications. Each emulsion required oil phase, water phase, and 
emulsifier. The formulations are common formulations that are used in the industry. For a 
future study, it will be interesting to see if different compositions of oil phase, water 
phase, and especially emulsifier can contribute to the solubility of the APIs. 
Moreover, this research was checking the solubility of API in skin creams only. 
Another future study could be applying SP as emulsifier also in gels and lotions.  
 
Micelle Characterizations. The theory behind the results that were observed in my 
study related mostly to the formation of polymeric micelle between the polymers and the 
drugs. Future in depth studies could be used to verify the results in my thesis. Currently 
some work is being done to observe if there is a change of the micelle’ size due to 
temperature change or concentration change. Also, some work was done on a mixture of 
API with emulsifier and SP to see the change in the micelles size. This work is done by 
using a dynamic light scattering (DLS) instrument. 
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Moreover, the micelles should be characterized not only when mixing an API 
with emulsifier and SP, but actual characterizing the micelle inside the oil phase and the 
water phase of the creams after centrifugation. 
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